Funding
Funding not disclosed
Founders
Product
Problem
Traditional autism diagnosis processes can extend for several years, delaying critical early interventions. This delay can significantly impact developmental outcomes for children diagnosed with Autism Spectrum Disorder (ASD).
Solution
NeuroQure offers the ASD Insight™ test, a novel skin-based assay designed for early autism risk detection. This technology enables risk assessment from as early as two days old, significantly earlier than traditional behavioral evaluations. By identifying potential risk factors months or years before behavioral signs manifest, ASD Insight™ allows for earlier behavioral assessment and the initiation of targeted interventions. This proactive approach can lead to improved developmental trajectories and better long-term outcomes for affected children. The test is processed in a CAP-accredited and CLIA-certified laboratory, ensuring clinical-grade accuracy and reliability.
Target Audience
The primary customers are pediatricians and healthcare providers seeking to integrate early autism risk detection into their practices to improve patient diagnosis journeys.
Features
- Non-invasive skin sample collection for autism risk assessment.
- Capable of risk detection in infants as young as two days old.
- Results are typically available within weeks of sample collection.
- Utilizes proprietary methodologies for autism risk diagnostics.
- Laboratory processing adheres to CAP accreditation and CLIA certification standards.
- Supports early intervention by identifying risk factors prior to observable behavioral symptoms.
- Genetic counselors are available to assist with patient result interpretation.